The B vitamins are eight water-soluble vitamins that function primarily as enzyme cofactors. B12, folate (B9), and B6 are the three most clinically significant for supplementation because their deficiency is common, their interactions (via the methylation cycle and homocysteine metabolism) are well-characterized, and the form of supplementation matters significantly. The critical insight for all three: the supplement form determines bioavailability, and the "standard" cheaper forms (cyanocobalamin, folic acid, pyridoxine HCl) are not always the most bioavailable — particularly in individuals with common genetic variants.
The methylation cycle is the metabolic pathway most directly relevant to B12, folate, and B6 supplementation. In this cycle, homocysteine is converted to methionine using B12 as a cofactor and methylfolate (5-MTHF) as the methyl donor. Methionine is converted to SAM (S-adenosylmethionine), the universal methyl donor for hundreds of biochemical reactions including DNA methylation, neurotransmitter synthesis, and gene expression regulation. B6 is required at a separate step converting homocysteine to cystathionine via the transsulfuration pathway. When any of these B vitamins are deficient, homocysteine accumulates — serving as the biomarker of methylation cycle dysfunction.
| Vitamin | Standard Form | Active/Preferred Form | Why It Matters | Dose |
|---|---|---|---|---|
| B12 | Cyanocobalamin | Methylcobalamin or adenosylcobalamin | Cyanocobalamin must be converted to active forms (methyl- and adenosyl-cobalamin) in the body; requires healthy renal function for cyanide clearance; methylcobalamin is more bioavailable and the primary form in the central nervous system; adenosylcobalamin is the mitochondrial form; either active form preferred, especially in elderly, kidney disease, or neurological symptoms | General: 500–1000mcg/day methylcobalamin. Deficiency repletion: 1000mcg/day × 1 month, then maintenance. Sublingual or IM injection for severe deficiency or malabsorption (pernicious anemia) |
| Folate (B9) | Folic acid (synthetic oxidized form) | 5-MTHF (methylfolate, L-methylfolate) | Folic acid requires MTHFR enzyme conversion to active 5-MTHF; MTHFR C677T TT genotype: 70% reduced conversion; folic acid accumulates as UMFA (unmetabolized folic acid) in some individuals; methylfolate (Quatrefolic or Metafolin brands) bypasses MTHFR entirely; safe for all genotypes; preferred for supplementation, especially pregnancy and MTHFR variants | General: 400–800mcg 5-MTHF/day. Pregnancy: 800mcg–1mg 5-MTHF. MTHFR TT: 1mg 5-MTHF (start low — some report "overmethylation" symptoms at high doses; titrate up) |
| B6 | Pyridoxine HCl | P-5-P (pyridoxal-5-phosphate) | Pyridoxine HCl must be converted to P-5-P in the liver; conversion can be impaired in liver disease, inflammation, or magnesium deficiency; P-5-P is the directly active coenzyme form; pyridoxine HCl at high doses accumulates and may be neurotoxic; P-5-P is thought to carry lower neurotoxicity risk at equivalent doses, though high-dose P-5-P has not been extensively studied for safety | General: 1.3–2mg P-5-P (from food or standard multivitamin). Therapeutic (homocysteine, PMS): 25–50mg P-5-P. Never exceed 100mg/day without physician guidance. Avoid high-dose pyridoxine HCl entirely |
| B12 sublingual vs oral | Oral tablet | Sublingual or liquid drops | B12 absorption from oral tablets requires intact intrinsic factor (produced by gastric parietal cells); intrinsic factor production declines with age and is absent in pernicious anemia; sublingual B12 is absorbed directly through oral mucosa (bypasses intrinsic factor); equally effective as IM injection in most studies; preferred for elderly, those on PPIs/H2 blockers (reduce gastric acid → reduce intrinsic factor), and pernicious anemia patients | Sublingual 1000mcg methylcobalamin dissolving tablet or liquid; hold under tongue 30 seconds before swallowing |
Vegans and vegetarians: B12 supplementation is not optional — it is essential; B12 occurs in nature only in animal products; algae and fermented plant foods contain B12 analogs that do not function as human B12; supplement methylcobalamin 1000mcg/day sublingual; retest serum B12 and MMA after 3 months to confirm adequacy. Folate and B6 are generally adequate from plant-based diets. Consider a comprehensive B complex covering all eight B vitamins as insurance.
MTHFR variant carriers: Test via 23andMe, AncestryDNA, or specific MTHFR genetic panel; if C677T TT (homozygous), supplement with 5-MTHF (methylfolate) 400–800mcg/day rather than folic acid; avoid folic acid-fortified foods if possible; also supplement B12 methylcobalamin (methylation cycle requires both); check homocysteine levels — target <8 μmol/L; add B6 25–50mg P-5-P if homocysteine remains elevated after B12 + methylfolate supplementation.
Adults over 50 / metformin users / PPI users: All three populations have impaired B12 absorption; sublingual methylcobalamin 1000mcg/day preferred over oral tablets; test serum B12 AND methylmalonic acid (MMA) — MMA is more sensitive for functional deficiency than serum B12 alone; serum B12 can be falsely normal while functional deficiency (elevated MMA) is present; annual B12 monitoring recommended for long-term PPI and metformin users.
Homocysteine reduction protocol: If homocysteine >10 μmol/L: methylcobalamin 1000mcg + 5-MTHF 800mcg + B6 (P-5-P) 25–50mg daily; retest homocysteine at 3 months; target <8 μmol/L; if homocysteine persists elevated despite B vitamin adequacy, evaluate kidney function (reduced clearance) and consider betaine (trimethylglycine) 1–3g/day as additional methyl donor.
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.